USE OF EXTERNAL CONTROL DATA TO ADJUST FOR TREATMENT SWITCHING IN COST-EFFECTIVENESS ANALYSES: LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS STANDARD OF CARE (SOC) IN SECOND-LINE RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA

被引：0
|
作者：
Chandler, C. [1 ]
Liu, F. F. [2 ]
Klijn, S. [2 ]
Elsada, A. [3 ]
Proskorovsky, I [4 ]
机构：
[1] Evidera PPD, Waltham, MA USA
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Bristol Myers Squibb, Denham, Bucks, England
[4] Evidera PPD, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MSR78
引用
收藏
页码：S407 / S408
页数：2
相关论文
共 50 条
  • [21] Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
    Christopher Parker
    Fei Fei Liu
    Kristen A. Deger
    Conrado Franco-Villalobos
    Irina Proskorovsky
    Scott J. Keating
    Sonja Sorensen
    Advances in Therapy, 2023, 40 : 2355 - 2374
  • [22] Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
    Bachier, Carlos R.
    Godwin, John E.
    Andreadis, Charalambos
    Palomba, Maria Lia
    Abramson, Jeremy S.
    Sehgal, Alison R.
    Hildebrandt, Gerhard
    Stevens, Don A.
    Hoda, Daanish
    Licitra, Edward J.
    Siddiqi, Tanya
    Farazi, Thalia Andrea
    Kostic, Ana
    Trede, Nikolaus S.
    Wang, Lei
    Lymp, James
    Maloney, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.
    Sehgal, Alison R.
    Hildebrandt, Gerhard
    Ghosh, Nilanjan
    Godwin, John E.
    Wagner-Johnston, Nina D.
    Hoda, Daanish
    Licitra, Edward J.
    Munoz, Javier
    Trede, Nikolaus S.
    Wang, Lei
    Thorpe, Jerill
    Gordon, Leo, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
    Gordon, Leo I.
    Liu, Fei Fei
    Braverman, Julia
    Hoda, Daanish
    Ghosh, Nilanjan
    Hamadani, Mehdi
    Hildebrandt, Gerhard C.
    Peng, Lily
    Guo, Shien
    Shi, Ling
    Sehgal, Alison
    HAEMATOLOGICA, 2024, 109 (03) : 857 - 866
  • [25] Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion
    Siddiqi, Tanya
    Jaeger, Ulrich
    Moshkovich, Olga
    Braverman, Julia
    Liu, Fei Fei
    Lanar, Sally
    Miera, Matthew
    Shah, Selam
    Devlen, Jennifer
    Salles, Gilles
    BLOOD, 2021, 138
  • [26] Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma
    Saeedian, Matia
    Badaracco, Jack
    Botros, Afraim
    Gitlin, Matthew
    Keating, Scott J.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (11): : 712.e1 - 712.e7
  • [27] Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study
    Sehgal, Alison R.
    Godwin, John
    Pribble, John
    Wang, Lei
    Thorpe, Jerill
    Hildebrandt, Gerhard C.
    BLOOD, 2019, 134
  • [28] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Maloney, David G.
    Kuruvilla, John
    Fox, Christopher P.
    Cartron, Guillaume
    Li, Daniel
    Hasskarl, Jens
    Bonner, Ashley
    Zhang, Yixie
    Liu, Fei Fei
    BLOOD, 2020, 136
  • [29] Safety and Efficacy Results From Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) In Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Abramson, Jeremy
    Palomba, M. Lia
    Gordon, Leo
    Lunning, Matthew
    Wang, Michael
    Arnason, Jon
    Mehta, Amitkumar
    Purev, Enkhtsetseg
    Maloney, David
    Andreadis, Charalambos
    Sehgal, Alison
    Solomon, Scott
    Ghosh, Nilanjan
    Albertson, Tina
    Garcia, Jacob
    Kostic, Aria
    Li, Daniel
    Kim, Yeonhee
    Siddiqi, Tanya
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 215 - 215
  • [30] THE COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS SECOND-LINE THERAPY IN PATIENTS WITH LARGE B-CELL LYMPHOMA IN ITALY
    Rodriguez-Guadarrama, Yael
    Cortesi, Paolo Angelo
    Dondoni, Cristina
    Blissett, Rob
    Smith, Nathaniel
    van Hees, Frank
    Vadgama, Sachin
    BONE MARROW TRANSPLANTATION, 2024, 59 : 768 - 769
12345